Gastric Bleeding and Benorylate, a New AspirinBr Med J 1972; 3 doi: https://doi.org/10.1136/bmj.3.5826.545 (Published 02 September 1972) Cite this as: Br Med J 1972;3:545
- D. N. Croft,
- J. H. P. Cuddigan,
- Carole Sweetland
Benorylate (4-acetamidophenyl 2-acetoxybenzoate) is a new esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin. Gastrointestinal blood loss, measured with 51Cr-labelled red cells, during benorylate therapy was compared with that during therapy with soluble aspirin in 15 subjects, a simplified crossover procedure being used. Mean blood loss during benorylate therapy was 1·7 ml/day which was significantly less than that during therapy with soluble aspirin (5·1 ml/day; P <0·001). In 12 of the 15 patients blood loss with benorylate was less than 2·5 ml/day. Benorylate appears to be a definite improvement on current formulations of aspirin and should be a useful drug for the treatment of patients with chronic rheumatic disorders.